Since the outbreak of the COVID-19 pandemic, the Covishield vaccine has been widely administered in India. Manufactured by the Serum Institute of India, Covishield is based on the formula developed by AstraZeneca and Oxford University. However, recent news reveals that AstraZeneca has acknowledged the possibility of rare side effects associated with the vaccine. This admission came after a case was brought to the High Court of the UK, shedding light on the potential risks of Covishield. In this blog post, we will delve into the details of this development, including the rare side effect known as Thrombocytopenia Syndrome (TTS).
Background:
In early 2021, several countries banned the use of Covishield due to concerns over its safety. However, it was only recently that AstraZeneca admitted the potential for rare side effects associated with the vaccine. The admission came as a result of a case filed in the UK High Court, which revealed the existence of TTS. AstraZeneca submitted a document in February 2023, acknowledging the link between Covishield and TTS.
How many people have taken Covishield
Covisheild was widely administered in India which accounts for approx. 1700 mn.
Understanding Thrombocytopenia Syndrome (TTS):
TTS, which stands for Thrombocytopenia Syndrome, is a rare condition characterized by blood clotting. It has been observed in cases involving vaccines based on adenovirus, such as Covishield. TTS can lead to blood clotting in various parts of the body, including the brain. This can result in severe headaches, blurred vision, difficulty speaking, chest pain, abdominal pain, and breathing difficulties. Additionally, TTS can cause a decrease in platelet levels, leading to further complications.
The Impact and Response:
Following reports of blood clotting cases associated with Covishield, several countries, including Denmark, Ireland, Thailand, Netherlands, Norway, Iceland, Congo, and Bulgaria, banned the vaccine. Subsequently, Germany, France, Italy, Spain, Canada, Sweden, Latvia, Slovenia, Australia, Indonesia, and Malaysia also halted its use. However, the World Health Organization (WHO) stated in March 2021 that the benefits of the AstraZeneca vaccine outweighed the risks, leading to its continued use.
What can we do now?
Most of us has already taken Covi sheild. Now we can only stay informed about the possible complications. To prevent thrombosis with thrombocytopenia syndrome (TTS), which is a rare side effect associated Covishield (AstraZeneca), here are some general guidelines:
Stay Informed: Educate yourself about the symptoms of TTS and the vaccines associated with it. Awareness can help you recognize any potential signs early.
Follow Vaccine Guidelines: If you’re eligible for a COVID-19 vaccine, discuss any concerns with your healthcare provider before getting vaccinated. They can provide information specific to your health status and guide you on the best course of action.
Report Symptoms Promptly: The symptoms of TTS include severe headache, blurred vision, difficulty speaking, chest pain, abdominal pain, shortness of breath, and leg swelling, among others. Prompt reporting and diagnosis are crucial for managing TTS effectively.
Medical Evaluation: If you have a history of blood clotting disorders or other risk factors for TTS, discuss them with your healthcare provider before vaccination. They can help assess your individual risk and recommend appropriate measures.
Alternative Vaccines: If you’re concerned about the risk of TTS associated with a specific vaccine, consult your healthcare provider about alternative vaccine options available in your region. Different vaccines may have different risk profiles, and your provider can help you make an informed decision based on your health status.
Stay Updated: Keep yourself informed about the latest guidance and recommendations from health authorities regarding COVID-19 vaccines and associated risks. Guidelines may evolve as more data become available, so staying updated is important.
The admission by AstraZeneca regarding the potential rare side effects of the Covishield vaccine has raised concerns about its safety. Thrombocytopenia Syndrome (TTS) has been observed in cases involving vaccines based on adenovirus, including Covishield. While several countries initially banned the vaccine, the WHO has maintained that its benefits outweigh the risks. It is important to stay informed about the latest developments and consult with healthcare professionals for personalized guidance on vaccination decisions.